Ionizable Lipids for mRNA Delivery via Composite Nanoparticles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering nucleic acids, such as mRNA and oligonucleotides, face challenges including susceptibility to nuclease digestion in plasma and limited ability to access intracellular compartments, necessitating improved lipids and lipid nanoparticles for protection and effective delivery.
Innovation Solution
Development of novel lipids that form lipid nanoparticles in combination with other lipid components like neutral lipids, charged lipids, and polymer conjugated lipids to shield nucleic acids from degradation and facilitate cellular uptake, enhancing their therapeutic index and delivery efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If free nucleic acids are administered, then delivery to intracellular compartment is limited, but susceptibility to nuclease digestion in plasma increases
Solution Approach 1:
The patent employs composite lipid nanoparticles comprising multiple lipid components (ionizable lipid, neutral lipid, cholesterol, PEGylated lipid) to create a delivery system that simultaneously protects nucleic acids from plasma nucleases and facilitates cellular uptake. The composite structure allows different lipid components to perform specialized functions: ionizable lipids enable endosomal escape, PEGylated lipids provide steric protection and circulation stability, cholesterol maintains membrane fluidity, and neutral lipids form the core structure.
Solution Approach 2:
The lipid nanoparticle forms a flexible protective shell around the nucleic acid payload. The lipid bilayer structure acts as a thin film barrier that protects the encapsulated nucleic acid from external nucleases in plasma while remaining dynamic enough to facilitate cellular membrane fusion and endosomal escape, thus simultaneously providing protection and enabling cellular uptake.
2Reliability
If lipid nanoparticles are used to protect nucleic acids, then protection from degradation is improved, but optimal drug:lipid ratios and therapeutic index need optimization
Solution Approach 1:
The patent systematically optimizes critical formulation parameters including the molar ratios of different lipid components (ionizable lipid:neutral lipid:cholesterol:PEGylated lipid), the pKa of the ionizable lipid, the chain length and saturation of fatty acid chains, and the PEG chain length. These parameter optimizations enable control over nanoparticle size, charge, stability, and cellular uptake efficiency, achieving optimal protection and therapeutic index.
Solution Approach 2:
The lipid nanoparticle formulation is designed to be dynamic rather than static. The ionizable lipid component changes its charge state in response to pH changes (neutral at physiological pH, positive in endosomes), enabling the nanoparticle to adapt its properties during circulation and cellular uptake. This dynamic behavior simplifies formulation by allowing a single composition to perform multiple functions across different biological environments.
3Ease of manufacture
If conventional lipids are used, then manufacturing is simpler, but delivery efficacy and therapeutic index are reduced
Solution Approach 1:
The ionizable lipid acts as an intermediary molecule that bridges the nucleic acid payload and the cellular delivery machinery. Its unique structure with ionizable amine groups, hydrophobic chains, and head groups allows it to interact with both the nucleic acid (through electrostatic interactions) and cellular membranes (through fusion or endosomal disruption), thereby enabling effective delivery without requiring complex manufacturing processes.
Solution Approach 2:
The ionizable lipid component performs multiple functions within a single molecular structure: it forms the nanoparticle core, provides steric and electrostatic protection, enables pH-responsive endosomal escape, and facilitates cellular membrane interaction. This multi-functionality reduces the need for multiple separate components or complex manufacturing steps, maintaining ease of manufacture while achieving high delivery efficacy.
Data Source
AI summary
Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein X, Y, L1, L2, L3, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.